Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo controlled non-inferiority trial

Trial Profile

Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo controlled non-inferiority trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs ASF 1057 (Primary) ; Ketoconazole
  • Indications Seborrhoeic dermatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Astion Pharma A/S
  • Most Recent Events

    • 02 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top